Concerning the β2-AR, Huang et al. [103] found that HF patients carrying the Arg16Gly polymorphic variant of this receptor had a worse prognosis, but responded better to β-blocker treatment than those presenting the Arg16 variant. This evidence concerns the gene ADRB2 and hydrops fetalis.